Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-Zosano Pharma Says Resubmitted Its M207 505(B)(2) NDA To U.S. FDA

BY Reuters
— 8:49 AM ET 01/24/2022

Jan 24 (Reuters) - Zosano Pharma Corp (ZSAN):

* ZOSANO PHARMA CORP (ZSAN) - ON JAN 18,, RESUBMITTED ITS M207 (ZOLMITRIPTAN TRANSDERMAL MICRONEEDLE SYSTEM) 505(B)(2) NDA TO U.S. FDA Source: (https://bit.ly/3Iyexg8) Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More ZSAN News

CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
GlobeNewswire - 12:01 PM ET 01/05/2022
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
GlobeNewswire - 9:20 AM ET 01/05/2022
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
GlobeNewswire - 4:30 PM ET 12/13/2021